Overview

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer

Status:
Recruiting

Trial end date:
2026-02-06

Target enrollment:

Participant gender:

Summary

20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory Cervical and Endometrial Cancer.

Phase:

Early Phase 1

Details

Lead Sponsor:

Shanghai Yunying Medical Technology

Collaborator:

Shanghai 10th People's Hospital